AVALO THERAPEUTICS, INC. Research and Development Expense (Excluding Acquired in Process Cost)
AVALO THERAPEUTICS, INC. (AVTX) reported Research and Development Expense (Excluding Acquired in Process Cost) of $23.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2026-08-06
- AVALO THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2026-06-30 was $23.42M, a 66.39% increase year-over-year.
- AVALO THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2026-03-31 was $14.05M, a 53.97% increase year-over-year.
- AVALO THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2025-12-31 was $13.27M, a 62.13% increase year-over-year.
- AVALO THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2025-09-30 was $13.62M, a 42.81% increase year-over-year.
- AVALO THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for fiscal 2025 was $50.08M, a 104.95% increase from fiscal 2024.
- AVALO THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for fiscal 2024 was $24.44M, a 77.29% increase from fiscal 2023.
- AVALO THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for fiscal 2023 was $13.78M, a 55.97% decline from fiscal 2022.
- AVALO THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for fiscal 2022 was $31.31M, a 47.68% decline from fiscal 2021.
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 3 month | Research and Development Expense (Excluding Acquired in Process Cost) 3 month as first filed | Research and Development Expense (Excluding Acquired in Process Cost) 6 month | Research and Development Expense (Excluding Acquired in Process Cost) 6 month as first filed | Research and Development Expense (Excluding Acquired in Process Cost) 9 month | Research and Development Expense (Excluding Acquired in Process Cost) 9 month as first filed | Research and Development Expense (Excluding Acquired in Process Cost) 12 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $23.42M 10-Q · filed 2026-08-06 | $37.47M 10-Q · filed 2026-08-06 | $50.73M derived: sum of 3 quarters · filed 2026-08-06 | $64.35M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $14.05M 10-Q · filed 2026-05-13 | $27.31M derived: sum of 2 quarters · filed 2026-05-13 | $40.94M derived: sum of 3 quarters · filed 2026-05-13 | $55.01M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $13.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $26.89M derived: sum of 2 quarters · filed 2026-03-23 | $40.96M derived: sum of 3 quarters · filed 2026-08-06 | $50.08M 10-K · filed 2026-03-23 | ||||
| 2025-09-30 | $13.62M 10-Q · filed 2025-11-06 | $27.70M derived: sum of 2 quarters · filed 2026-08-06 | $36.82M 10-Q · filed 2025-11-06 | $45.00M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $14.07M 10-Q · filed 2026-08-06 | $23.20M 10-Q · filed 2026-08-06 | $31.38M derived: sum of 3 quarters · filed 2026-08-06 | $40.92M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $9.12M 10-Q · filed 2026-05-13 | $17.31M derived: sum of 2 quarters · filed 2026-05-13 | $26.84M derived: sum of 3 quarters · filed 2026-05-13 | $31.45M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $8.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $17.72M derived: sum of 2 quarters · filed 2026-03-23 | $22.32M derived: sum of 3 quarters · filed 2026-03-23 | $24.44M 10-K · filed 2026-03-23 | ||||
| 2024-09-30 | $9.54M 10-Q · filed 2025-11-06 | $14.14M derived: sum of 2 quarters · filed 2025-11-06 | $16.25M 10-Q · filed 2025-11-06 | $18.12M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | $4.60M 10-Q · filed 2025-08-07 | $6.72M 10-Q · filed 2025-08-07 | $8.58M derived: sum of 3 quarters · filed 2025-08-07 | $9.83M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $2.12M 10-Q · filed 2025-05-12 | $3.98M derived: sum of 2 quarters · filed 2025-05-12 | $5.23M derived: sum of 3 quarters · filed 2025-05-12 | $9.89M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $3.12M derived: sum of 2 quarters · filed 2025-03-20 | $7.77M derived: sum of 3 quarters · filed 2025-03-20 | $13.78M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $1.25M 10-Q · filed 2024-11-07 | $5.91M derived: sum of 2 quarters · filed 2024-11-07 | $11.92M 10-Q · filed 2024-11-07 | $18.09M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $4.66M 10-Q · filed 2024-08-12 | $10.67M 10-Q · filed 2024-08-12 | $16.84M derived: sum of 3 quarters · filed 2024-08-12 | $23.88M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $6.01M 10-Q/A · filed 2024-07-11 | $12.18M derived: sum of 2 quarters · filed 2024-07-11 | $19.22M derived: sum of 3 quarters · filed 2024-07-11 | $27.73M derived: sum of 4 quarters · filed 2024-07-11 | ||||
| 2022-12-31 | $6.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $13.21M derived: sum of 2 quarters · filed 2024-03-29 | $21.72M derived: sum of 3 quarters · filed 2024-03-29 | $31.31M 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $7.04M 10-Q · filed 2023-11-09 | $15.55M derived: sum of 2 quarters · filed 2023-11-09 | $25.14M 10-Q · filed 2023-11-09 | $36.65M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | $8.51M 10-Q · filed 2023-08-03 | $18.09M 10-Q · filed 2023-08-03 | $29.60M derived: sum of 3 quarters · filed 2023-08-03 | $40.16M derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2022-03-31 | $9.58M 10-Q · filed 2023-05-04 | $21.09M derived: sum of 2 quarters · filed 2023-05-04 | $31.64M derived: sum of 3 quarters · filed 2023-05-04 | $44.21M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2021-12-31 | $11.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $22.06M derived: sum of 2 quarters · filed 2023-03-29 | $34.63M derived: sum of 3 quarters · filed 2023-03-29 | $59.84M 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | $10.55M 10-Q · filed 2022-11-07 | $23.12M derived: sum of 2 quarters · filed 2022-11-07 | $48.33M 10-Q · filed 2022-11-07 | $60.96M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2021-06-30 | $12.57M 10-Q · filed 2022-08-04 | $37.77M 10-Q · filed 2022-08-04 | $50.41M derived: sum of 3 quarters · filed 2022-08-04 | $59.28M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $25.21M 10-Q · filed 2022-05-05 | $37.84M derived: sum of 2 quarters · filed 2022-05-05 | $46.72M derived: sum of 3 quarters · filed 2022-05-05 | $52.63M derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | $12.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $21.51M derived: sum of 2 quarters · filed 2022-03-02 | $27.43M derived: sum of 3 quarters · filed 2022-03-02 | $32.19M 10-K · filed 2022-03-02 | $32.19M 10-K · filed 2021-03-08 | |||
| 2020-09-30 | $8.87M 10-Q · filed 2021-11-09 | $8.87M 10-Q · filed 2020-11-09 | $14.79M derived: sum of 2 quarters · filed 2021-11-09 | $19.56M 10-Q · filed 2021-11-09 | $19.56M 10-Q · filed 2020-11-09 | $22.46M derived: sum of 4 quarters · filed 2021-11-09 | ||
| 2020-06-30 | $5.92M 10-Q · filed 2021-08-02 | $5.92M 10-Q · filed 2020-08-06 | $10.69M 10-Q · filed 2021-08-02 | $10.68M 10-Q · filed 2020-08-06 | $13.59M derived: sum of 3 quarters · filed 2021-08-02 | $15.34M derived: sum of 4 quarters · filed 2021-08-02 | ||
| 2020-03-31 | $4.77M 10-Q · filed 2021-05-13 | $4.77M 10-Q · filed 2020-05-07 | $7.67M derived: sum of 2 quarters · filed 2021-05-13 | $9.42M derived: sum of 3 quarters · filed 2021-05-13 | $13.13M derived: sum of 4 quarters · filed 2021-05-13 | |||
| 2019-12-31 | $2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $4.65M derived: sum of 2 quarters · filed 2021-03-08 | $8.36M derived: sum of 3 quarters · filed 2021-03-08 | $11.76M 10-K · filed 2021-03-08 | ||||
| 2019-09-30 | $1.74M 10-Q · filed 2020-11-09 | $5.46M derived: sum of 2 quarters · filed 2020-11-09 | $8.86M 10-Q · filed 2020-11-09 | $10.86M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-06-30 | $3.71M 10-Q · filed 2020-08-06 | $7.11M 10-Q · filed 2020-08-06 | $9.12M derived: sum of 3 quarters · filed 2020-08-06 | $10.17M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | $3.40M 10-Q · filed 2020-05-07 | $5.41M derived: sum of 2 quarters · filed 2020-05-07 | $6.46M derived: sum of 3 quarters · filed 2020-05-07 | $7.54M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $3.05M derived: sum of 2 quarters · filed 2020-03-11 | $4.14M derived: sum of 3 quarters · filed 2020-03-11 | $5.79M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | $1.05M 10-Q · filed 2019-11-14 | $2.13M derived: sum of 2 quarters · filed 2019-11-14 | $3.78M 10-Q · filed 2019-11-14 | |||||
| 2018-06-30 | $1.08M 10-Q · filed 2019-08-08 | $2.73M 10-Q · filed 2019-08-08 | ||||||
| 2017-09-30 | $964.57K 10-Q · filed 2018-11-13 | $2.41M 10-Q · filed 2018-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |